Italian Registry of Cardiovascular Magnetic Resonance on Congenital Anomalies of the Coronary Arteries (ITACA-Registry)
Launched by ITAB - INSTITUTE FOR ADVANCED BIOMEDICAL TECHNOLOGIES · Dec 30, 2020
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
Congenital coronary anomalies (ACC) are relatively rare heart disease, in which a congenital defect of origin, course, and term, of one or more epicardial cardiac coronary arteries, is recognized. The global prevalence is estimated at around 0.6-0.7% in the general population, where the most frequent ACCs consist of the anomalous origin of the right coronary artery from the left breast (ARCA), with a prevalence of 0.23%; while the anomalous origin from the Sn coronary artery from the right breast (ALCA) would seem to have a prevalence of 0.03%.
ACCs have often been associated with an incre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with anomalous origin of the coronaries diagnosed with cardiac magnetic resonance imaging
- Exclusion Criteria:
- • Patients with known ischemic heart disease
- • Patients with coronary atherosclerotic disease
About Itab Institute For Advanced Biomedical Technologies
Itab - Institute for Advanced Biomedical Technologies is a leading research organization dedicated to advancing the field of biomedical innovation through rigorous clinical trials and cutting-edge scientific exploration. Committed to improving patient outcomes, itab focuses on developing novel therapeutic strategies and medical technologies that address unmet clinical needs. With a team of experienced researchers and healthcare professionals, itab fosters collaboration and utilizes state-of-the-art methodologies to ensure the highest standards of safety and efficacy in its clinical programs. Through its mission to translate scientific breakthroughs into real-world applications, itab plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ancona, , Italy
Patients applied
Trial Officials
Francesco Bianco, M.D.
Principal Investigator
Ospedali Riuniti Ancona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials